Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:
” ‘The FDA has approved Cablivi (caplacizumab) for injection to treat pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.’
‘Caplacizumab therapy is nanobody-based and built on small antibody fragments derived from heavy-chain-only antibodies, that targets von Willebrand factor, a protein that plays a central role in platelet adhesion and clot formation in aTTP.
It works by binding to the A1 domain of von Willebrand factor, blocking its interaction with platelets and helping to reduce the microvascular clots that define the disease.’ ”
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 13:52Andrew Zapfel: Expanding Newborn Screening for Sickle Cell Disease in Africa
-
Apr 6, 2026, 13:45Svenja Tatjana Barckhausen: From Plasma Dependence to Self-Sufficiency in Africa
-
Apr 6, 2026, 13:35Gregory Piazza: When Antibodies Trigger Thrombosis
-
Apr 6, 2026, 13:24Paritosh Garg: Importance of Ruling Out an Underlying Cause Before Treatment of AIHA
-
Apr 6, 2026, 10:49Chokri Ben Lamine: Routine VTE Prophylaxis Is Not Recommended for Chronically Bedridden Patients at Home
-
Apr 6, 2026, 10:03Mohamed Sikkander Abdul Razak: Clinical Steps for Evaluating and Managing Heavy Menstrual Bleeding
-
Apr 6, 2026, 07:14Oliver Tiebel: Antiphospholipid Syndrome in Pregnancy – One of Hematology’s Most Complex Challenges
-
Apr 6, 2026, 06:25Katherine Bridge: My First Time at The EHA ReCon
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think